CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$42.24−0.38 (-0.89%)
Close on Nov 13, 2026Market cap $4.08BP/E –Yield –
CRISPR Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
CRISPR Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$513.83M. For fiscal 2025 it was -$645.09M. The highest annual figure on record is $391.48M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$645.09M | – |
| FY2024 | Dec 31, 2024 | -$447.31M | – |
| FY2023 | Dec 31, 2023 | -$202.70M | – |
| FY2022 | Dec 31, 2022 | -$648.99M | -265.8% |
| FY2021 | Dec 31, 2021 | $391.48M | – |
| FY2020 | Dec 31, 2020 | -$345.25M | -770.8% |
| FY2019 | Dec 31, 2019 | $51.47M | – |
| FY2018 | Dec 31, 2018 | -$155.42M | – |
| FY2017 | Dec 31, 2017 | -$61.62M | – |
| FY2016 | Dec 31, 2016 | -$67.21M | – |
| FY2015 | Dec 31, 2015 | -$25.60M | – |
| FY2014 | Dec 31, 2014 | -$6.59M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$125.81M | – |
| Q2 FY2026 | Jun 30, 2026 | -$112.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$125.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$149.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$127.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$224.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$143.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$59.75M | -180.2% |
| Q3 FY2024 | Sep 30, 2024 | -$105.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$146.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$135.75M | – |
| Q4 FY2023 | Dec 31, 2023 | $74.48M | – |
| Q3 FY2023 | Sep 30, 2023 | -$127.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$90.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$59.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$125.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$177.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$175.99M | -123.0% |
| Q1 FY2022 | Mar 31, 2022 | -$169.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$139.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$123.53M | – |
| Q2 FY2021 | Jun 30, 2021 | $766.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$111.83M | – |
| Q4 FY2020 | Dec 31, 2020 | -$105.20M | -947.3% |
| Q3 FY2020 | Sep 30, 2020 | -$90.06M | -164.1% |
| Q2 FY2020 | Jun 30, 2020 | -$78.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$71.50M | – |
| Q4 FY2019 | Dec 31, 2019 | $12.42M | – |
| Q3 FY2019 | Sep 30, 2019 | $140.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$53.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$47.61M | – |
| Q4 FY2018 | Dec 31, 2018 | -$44.28M | -2590.6% |
| Q3 FY2018 | Sep 30, 2018 | -$48.55M | – |
| Q2 FY2018 | Jun 30, 2018 | -$36.42M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.17M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.78M | – |
| Q3 FY2017 | Sep 30, 2017 | -$22.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -$20.60M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.02M | – |
| Q4 FY2016 | Dec 31, 2016 | -$24.90M | – |
See a number that looks wrong?